Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Jose C. Villasboas; Stephen M. Ansell

doi:10.1586/14737140.2016.1121812

Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Jose C. Villasboas, Stephen M. Ansell

Hematology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

Original language	English (US)
Pages (from-to)	5-12
Number of pages	8
Journal	Expert review of anticancer therapy
Volume	16
Issue number	1
DOIs	https://doi.org/10.1586/14737140.2016.1121812
State	Published - Jan 2 2016

Keywords

Hodgkin lymphoma
Immunotherapy
PD-1
PD-L1
checkpoint inhibitors
immunerelated adverse events
nivolumab

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/14737140.2016.1121812

Cite this

@article{be14837e4ebf4c0c943ef18d4a853c71,

title = "Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab",

abstract = "Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.",

keywords = "Hodgkin lymphoma, Immunotherapy, PD-1, PD-L1, checkpoint inhibitors, immunerelated adverse events, nivolumab",

author = "Villasboas, {Jose C.} and Ansell, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor and Francis.",

year = "2016",

month = jan,

day = "2",

doi = "10.1586/14737140.2016.1121812",

language = "English (US)",

volume = "16",

pages = "5--12",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "1",

}

TY - JOUR

T1 - Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

AU - Villasboas, Jose C.

AU - Ansell, Stephen M.

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

AB - Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

KW - Hodgkin lymphoma

KW - Immunotherapy

KW - PD-1

KW - PD-L1

KW - checkpoint inhibitors

KW - immunerelated adverse events

KW - nivolumab

UR - http://www.scopus.com/inward/record.url?scp=84955186084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955186084&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1121812

DO - 10.1586/14737140.2016.1121812

M3 - Article

C2 - 26577822

AN - SCOPUS:84955186084

VL - 16

SP - 5

EP - 12

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -

Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this